We evaluated the efficacy and safety of nimesulide (100 mg orally twice daily for > 48 hours) in a pilot series of five women (two with twin pregnancies) at 24+6 weeks (range 21+3-27+2) in preterm labour which was unresponsive to intravenous ritodrine. Nimesulide therapy was continued for eight days (5-16) and was associated with a prolongation of pregnancy of 27 days (6-69). Oligohydramnios occurred in all seven fetuses after three to nine days of therapy, and in the five pregnancies that continued after discontinuation of nimesulide, it resolved within four days (2-7). None of the babies manifested permanent renal damage.
Locatelli, A., Vergani, P., Bellini, P., Strobelt, N., Ghidini, A. (2001). Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin?. BJOG, 108(3), 325-326 [10.1016/S0306-5456(00)00071-1].
Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin?
LOCATELLI, ANNA;VERGANI, PATRIZIA;
2001
Abstract
We evaluated the efficacy and safety of nimesulide (100 mg orally twice daily for > 48 hours) in a pilot series of five women (two with twin pregnancies) at 24+6 weeks (range 21+3-27+2) in preterm labour which was unresponsive to intravenous ritodrine. Nimesulide therapy was continued for eight days (5-16) and was associated with a prolongation of pregnancy of 27 days (6-69). Oligohydramnios occurred in all seven fetuses after three to nine days of therapy, and in the five pregnancies that continued after discontinuation of nimesulide, it resolved within four days (2-7). None of the babies manifested permanent renal damage.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
